RiteshParajuliMD

Clinical Trials

• Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments Start of enrollment: 2017 Aug 14

  Active, not recruiting

  Phase 2

• Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer Start of enrollment: 2019 Apr 05

  Active, not recruiting

  Phase 3

• Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer Start of enrollment: 2018 Feb 27

  Active, not recruiting

  Phase 1, Phase 2

• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer Start of enrollment: 2019 Oct 02

  Recruiting

  Phase 3

• A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer Start of enrollment: 2019 Aug 14

  Terminated

  Phase 4

• Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer Start of enrollment: 2020 Jul 23

  Terminated

  Phase 2

• Join now to see all